Navigation Links
Immunosyn Corporation to Begin Trading
Date:10/23/2007

LA JOLLA, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) announced that its stock will begin over-the- counter trading on Friday, October 26, 2007. The company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, distribute and sell the biopharmaceutical SF-1019.

"Having gone public in January this year, we are pleased to start trading as we begin to develop the distribution lines for a product as important as SF-1019," noted Stephen Ferrone, Immunosyn's CEO.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including auto-immune disorders such as Multiple Sclerosis (MS), neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS) and complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and Diabetic Ulcers (DU).

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Immunosyn Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
2. Risk of heart disease begins in teens
3. Experts Recommend Preventive Measures For Avian Flu To Begin From Farms
4. Researchers Begin Study To Find Out If Angioplasty Can Be Safely Done In Smaller Hospitals
5. Cancer Begins With Epigenetic Changes: Study
6. Learning About Healthy Diet Choices Begins At Schools
7. China Begins Human Trials For HIV/AIDS Drug
8. Pilot Study to Test Effect of Mobile Phone Transmissions On Skin To Begin In Finland
9. Preparation for Culling Begin at Belghat, Rajangaon and Dhaamnia
10. Make-Up Tips For Beginners
11. Jalgaon: Third Phase Of Culling Operations Begin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... ... 14, 2017 , ... AgileMinder develops innovative products and services that bring "Care, ... available on Apple as a fun, free emoji sticker pack for iMessage. Use the ... ten color coded values on The Emoji Scale. , On Apple: "The Emoji ...
(Date:1/13/2017)... ... January 13, 2017 , ... ... sugar levels. Counting carbohydrates is as easy as checking the nutrition label on ... affects blood sugar levels. Despite being sugar-free, proteins can influence — either positively ...
(Date:1/13/2017)... , ... January 13, 2017 , ... A January 10 ... five procedures for 2017 according to the publication, with an emphasis on some new ... Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., who is known more casually to his patients and colleagues ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... ... Moody Zook has taken on the challenge of providing additional organic alternatives for ... During the launch of the brand’s new line of all-natural activated charcoal products, ...
(Date:1/13/2017)... ... ... An inventor from Virginia Beach, Va., is always on the lookout for ... outfits, so he decided to design something that enhances the look of a belt, ... belt to allow for quick, easy changing of its look. This not only diversifies ...
Breaking Medicine News(10 mins):
(Date:1/12/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it has concluded agreements with the U.S. Department of ... (SEC) to resolve the previously disclosed U.S. Foreign Corrupt ... as in relation to the former deferred prosecution agreement ... with DOJ and SEC, respectively, on March 26, 2012.  ...
(Date:1/12/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... findings at this week,s Orlando Dermatology Aesthetic & Clinical (ODAC) ... acnes -induced inflammation. The data will be shared ... Acne Pathogenesis," at ODAC, which is being held Jan. 13-16 ... ...
(Date:1/12/2017)... -- This new report from VPGMarketResearch contains 897 pages, ... German hospital microbiology testing market, including:  ... practice, as well as key economic, regulatory, demographic, social ... next ten years.  ... of major infectious diseases and microorganisms.  ...
Breaking Medicine Technology: